32 completed, 6 unknown, 3 terminated, 2 recruiting. 45 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Completed 32, Unknown 6, Terminated 3, Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 8, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Testosterone: new trials by email Literature Review of Testosterone trials Research Report on Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream - Vulvodynia, Dyspareunia | Phase 2 / Phase 3 | Not yet recruiting | TriHealth Inc. | 44 | 2025-12-01 | 2025-12-03 |
| Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering From Gender Dysphoria hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months, Cross sex hormones ( œstrogenes or testosterone) started at 15.5 years old +/- 6 months - Gender Dysphoria | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2024-06-25 | 2026-08-10 |
| Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy Testosterone gel, Placebo - Prostatic Neoplasms, Hypogonadism | Phase 3 | Recruiting | Canisius-Wilhelmina Hospital | 140 | 2022-12-12 | 2025-05-02 |
| Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study Testosterone gel, Placebo - Disorder of Sex Development, 46,XY | Phase 3 | Unknown | Erasmus Medical Center | 1 | 2021-06-01 | 2021-04-05 |
| Testopel ® vs. Generic Testosterone Pellets. Testopel 75mg Drug Implant, Testopel 100mg Drug Implant, Testopel 200mg Drug Implant - Hypogonadism | Phase 3 | Completed | University of Miami | 75 | 2020-03-12 | 2023-08-14 |
| Starting a Testosterone and Exercise Program After Hip Injury Testosterone, Placebo gel, Supervised exercise training - Hip Fracture, Frailty | Phase 3 | Completed | Washington University School of Medicine | 129 | 2019-03-05 | 2025-02-04 |
| Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men. Nasotestt 5 mg, Androgel 50 mg, Nasotestt Placebo - Hypogonadism | Phase 3 | Unknown | FBM Industria Brasileira Ltda | 228 | 2018-07-16 | 2017-09-19 |
| Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort Testosterone, Estradiol - Fertility Disorders | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 26 | 2017-08-01 | 2017-08-03 |
| Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men SOV2012-F1, AndroGel - Hypogonadism, Male | Phase 3 | Completed | Marius Pharmaceuticals | 314 | 2017-07-05 | 2023-06-28 |
| Systemic Hormones and Muscle Protein Synthesis Sustanon 250, Zoladex, Placebo - Sarcopenia, Muscle Hypotrophy | Phase 3 | Unknown | University of Nottingham | 34 | 2016-12-15 | 2019-02-26 |
| Effect of PROGRESSive Training and Teststerone in Older Frail Men testosterone, Progressive muscle training - Muscle Weakness | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 192 | 2016-11-01 | 2024-05-29 |
| Study of Testosterone vs Placebo in Testicular Cancer Survivors Testosterone, Placebos - Metabolic Syndrome, Testicular Cancer | Phase 2 / Phase 3 | Completed | Mikkel Bandak | 69 | 2016-11-01 | 2020-03-06 |
| Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness Testosterone cypionate, Standard nutrition and physical therapy at ICU - Critical Illness Polyneuropathies | Phase 2 / Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 30 | 2016-10-01 | 2017-02-01 |
| Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction Testosterone, Normal Saline - Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase | Phase 2 / Phase 3 | Withdrawn | Texas Tech University Health Sciences Center | 2016-08-01 | 2019-11-21 | |
| Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors Testosterone, Colecalciferol, Placebo drink solution - Hypogonadism, Pre-frail Seniors | Phase 3 | Terminated | University of Zurich | 91 | 2015-09-01 | 2020-06-18 |
| Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 133 | 2015-07-01 | 2018-03-30 |
| Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial Testosterone gel, Placebo gel - Infertility, Poor Ovarian Response | Phase 3 | Terminated | Fundacion Dexeus | 290 | 2015-04-01 | 2024-05-22 |
| Lifestyle Intervention and Testosterone Replacement in Obese Seniors Testosterone, Lifestyle Therapy, Placebo - Obesity and Hypogonadism | Phase 3 | Completed | VA Office of Research and Development | 83 | 2015-02-01 | 2022-07-26 |
| Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 150 | 2014-07-01 | 2018-02-07 |
| Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump - Primary Hypogonadism, Hypogonadotropic Hypogonadism | Phase 3 | Completed | Amneal Pharmaceuticals, LLC | 32 | 2014-03-01 | 2014-06-26 |
Showing 20 of 45. Sign in to see all of them.
Hypogonadism (16) · Eunuchism (3) · Motor Activity (3) · Sexual Dysfunctions, Psychological (3) · Frailty (2) · Hip Fractures (2) · Infertility (2) · Muscular Atrophy (2) · Sarcopenia (2) · Anemia (1) · Anorexia Nervosa (1) · Arthralgia (1) · Bone Diseases, Metabolic (1) · Breast Neoplasms (1) · Burns (1)
Antares Pharma Inc. (2) · Hospital de Clinicas de Porto Alegre (2) · University of Washington (2) · VA Office of Research and Development (2) · Warner Chilcott (2) · Washington University School of Medicine (2) · Abbott (1) · Acerus Pharmaceuticals Corporation (1) · Alliance for Clinical Trials in Oncology (1) · Amneal Pharmaceuticals, LLC (1) · Aristotle University Of Thessaloniki (1) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Beersheva Mental Health Center (1) · Canisius-Wilhelmina Hospital (1)
United States (23) · France (4) · Denmark (3) · Germany (3) · United Kingdom (3) · Australia (2) · Finland (2) · Netherlands (2) · Spain (2) · Switzerland (2) · Austria (1) · Belgium (1) · Botswana (1) · Brazil (1) · Canada (1)
Stephanie T Page, MD, PhD (2) · Alastair Smith, MB, ChB (1) · Alessandro Silva, Director (1) · Andre van As, MD, PhD (1) · Anne Klibanski, M.D. (1) · Charles Loprinzi, MD (1) · Craig W Spellman, DO (1)
PMID 38224135, PMID 17105798, PMID 17592924, PMID 18987368, PMID 19734776, PMID 20881067, PMID 21252493, PMID 21717386, PMID 21761342, PMID 22321357, PMID 22463890, PMID 22606232, PMID 22895351, PMID 23150682, PMID 23303450, PMID 23343764, PMID 24009246, PMID 24298851, PMID 24655871, PMID 24824900, PMID 24918945, PMID 24968251, PMID 25211297, PMID 25481088, PMID 25514427, PMID 25548978, PMID 25807408, PMID 26554661, PMID 26695758, PMID 26886521, PMID 26956551, PMID 27171844, PMID 27172434, PMID 27355400, PMID 27433905, PMID 28240622, PMID 28241231, PMID 28241237, PMID 28241355, PMID 28241356, PMID 28673265, PMID 28840147, PMID 29253154, PMID 29500160, PMID 30366567, PMID 30612946, PMID 31551193, PMID 31784747, PMID 31958337, PMID 32372176
1UL1RR025758 (1), 2004 (1), 2014 (1), 2019 (1), P50GM060338 (1), R01AG037603 (1), R01AG037679 (1), R01DK052625 (1), U10CA037447 (1), UG1CA189823 (1)